Physician profile
Thomas Mark Johnson
NPI 1366498545
$1,961.98
in general payments reported to CMS, 2019-2025
20 companies · $294 in 2025
The $294 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $151 · 2021: $127 · 2022: $263 · 2023: $368 · 2024: $518 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,180.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $334.20 | 2021-2025 | Vabysmo |
| Astellas Pharma US INC | $192.06 | 2023-2025 | Izervay |
| Regeneron Healthcare Solutions, INC. | $171.64 | 2023-2025 | Eylea Hd, Eylea |
| Eyepoint US, INC. | $147.28 | 2019-2022 | |
| Abbvie INC. | $145.71 | 2022-2025 | |
| Apellis Pharmaceuticals, INC. | $131.48 | 2023-2025 | Syfovre |
| Bausch & Lomb Americas INC. | $123.10 | 2024 | Ic-8 Apthera Iol, Envista Mx60 Iol |
| Aerie Pharmaceuticals, INC. | $116.36 | 2020 | |
| Glaukos Corporation | $101.95 | 2019 | |
| Alimera Sciences, INC. | $93.54 | 2019-2024 | Iluvien, Yutiq |
| Allergan, INC. | $85.56 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $78.63 | 2024 | Acthar |
| Notal Vision, INC. | $74.13 | 2024 | Foresee Home |
| Ani Pharmaceuticals, INC. | $58.17 | 2025 | Iluvien |
| Novartis Pharmaceuticals Corporation | $39.72 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $28.56 | 2021 | |
| Sandoz INC. | $25.88 | 2024 | Cimerli |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.01 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.